Guan Xuehao, Zhang Rui, Zhang Guangfang, Wang Jian, Wang Shuguang, Liu Baoshan, Zhang Aiyuan
Hypertension is one of the leading epidemic factors of cardiovascular and cerebrovascular disease around the world. Many researchers have found that Sacubitril/Valsartan, the single angiotensin receptor-neprilysin inhibitor, played a critical role in lowering hypertension. However, Sacubitril/Valsartan’s indications and usage for hypertension has not been accepted in the world, except for China. The mechanism of Sacubitril/Valsartan’s antihypertensive effect is clear, including inhibiting renin-angiotensin system and reducing natriuretic peptides’ degradation. In this article, we retrieved and reviewed all clinical studies that explored the effect of Sacubitril/Valsartan or its safety in the treatment of hypertension patients. Most studies concluded that in comparison with traditional antihypertensive drugs (mainly including angiotensin receptor blockers or amlodipine), Sacubitril/Valsartan was firmly effective and safe. Thus, we deduce that Sacubitril/Valsartan’ indication for hypertension will be paid more attention and may be included in guideline for hypertension soon.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Hindi